One year after receiving three doses of a custom-built CRISPR base-editing therapy at Children’s Hospital of Philadelphia, ...

CRISPR Therapeutics stock has rebounded in the short term; however, over five years the share price is still significantly ...

CRISPR Therapeutics wins FDA pediatric approval for Casgevy, boosting market potential and pipeline upside despite slow uptake. Click here to read more.

WASHINGTON - The Food and Drug Administration Wednesday granted supplemental approval for a breakthrough CRISPR gene therapy ...

A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...

A team of researchers led by Professor Akitsu Hotta (Department of Clinical Application) developed a comprehensive framework ...

Stanford Medicine researchers have developed an artificial intelligence tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing "copilot" ...

Researchers in Basel have created SEED/Harvest, a new CRISPR-based technique that tags proteins without leaving any genetic “scars.” By blending two powerful methods, it allows scientists to study ...

When standard leukaemia treatments failed, 13-year-old Alyssa Tapley was told she had only weeks left – but then she was ...

The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.

In late June 2026, CRISPR Therapeutics AG was added to several Russell growth indexes, including the Russell 2000 Growth, ...

From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting ...